95.23 - 97.14
55.47 - 103.81
1.63M / 1.80M (Avg.)
55.57 | 1.74
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.20%
Revenue growth under 50% of FSM's 43.23%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-7.24%
Negative gross profit growth while FSM is at 94.84%. Joel Greenblatt would examine cost competitiveness or demand decline.
46.83%
EBIT growth below 50% of FSM's 5630.26%. Michael Burry would suspect deeper competitive or cost structure issues.
46.83%
Operating income growth under 50% of FSM's 5630.26%. Michael Burry would be concerned about deeper cost or sales issues.
22.02%
Net income growth under 50% of FSM's 213.26%. Michael Burry would suspect the firm is falling well behind a key competitor.
16.67%
EPS growth under 50% of FSM's 182.64%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
No Data
No Data available this quarter, please select a different quarter.
10.24%
Share count expansion well above FSM's 5.77%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.44%
Diluted share count expanding well above FSM's 5.77%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
14.42%
OCF growth under 50% of FSM's 977.98%. Michael Burry might suspect questionable revenue recognition or rising costs.
27.48%
FCF growth under 50% of FSM's 176.54%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
75.71%
10Y CAGR of 75.71% while FSM is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
No Data
No Data available this quarter, please select a different quarter.
-36.46%
Negative 3Y CAGR while FSM stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
936.18%
Below 50% of FSM's 3451.88%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-41.26%
Negative 3Y OCF/share CAGR while FSM stands at 235.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
657.46%
5Y net income/share CAGR above 1.5x FSM's 187.77%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-46.67%
Negative 3Y CAGR while FSM is 99.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
2332.51%
5Y equity/share CAGR above 1.5x FSM's 517.97%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
60.11%
3Y equity/share CAGR similar to FSM's 61.39%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
220.52%
Our AR growth while FSM is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
No Data
No Data available this quarter, please select a different quarter.
13.22%
Asset growth 1.25-1.5x FSM's 8.92%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
4.70%
BV/share growth above 1.5x FSM's 1.12%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-4.54%
We’re deleveraging while FSM stands at 63.05%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-1.31%
We cut SG&A while FSM invests at 4.64%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.